Show
Sort by
-
Efficacy of dupilumab in chronic rhinosinusitis with nasal polyps and comorbid asthma by baseline biomarkers of type 2 inflammation: SINUS-24 and SINUS-52 phase 3 trials
-
Liberty asthma traverse dupilumab shows sustained efficacy and improvements in asthma control and health-related quality of life (HRQOL) in patients with moderate-to-severe asthma
-
Dupilumab shows sustained efficacy and improvements in asthma control and health-related quality of life in patients with moderate-to-severe asthma : liberty asthma traverse
(2021) AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. In American Journal of Respiratory and Critical Care Medicine 203(9S). p.A1452-A1452 -
Long-term efficacy of dupilumab in patients with moderate-to-severe asthma in the liberty asthma traverse open-label extension study : improvements in asthma control and health-related quality of life
-
- Journal Article
- A1
- open access
Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP
-
- Conference Paper
- C3
- open access
Baseline characteristics of patients with chronic rhinosinusitis with nasal polyps and comorbid asthma from the pooled populations of the SINUS-24 and SINUS-52 Dupilumab phase 3 trials
-
Dupilumab improves patient-reported outcomes in chronic Rhinosinusitis with nasal polyps and comorbid asthma : sinus-24/sinus-52 trials